1. Home
  2. SUPN vs NVCR Comparison

SUPN vs NVCR Comparison

Compare SUPN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$51.77

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$13.44

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUPN
NVCR
Founded
2005
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
1.5B
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
SUPN
NVCR
Price
$51.77
$13.44
Analyst Decision
Strong Buy
Buy
Analyst Count
5
6
Target Price
$61.60
$28.42
AVG Volume (30 Days)
707.0K
1.8M
Earning Date
11-04-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$681,539,000.00
$642,269,000.00
Revenue This Year
$8.32
$9.75
Revenue Next Year
$23.36
$5.62
P/E Ratio
N/A
N/A
Revenue Growth
4.54
11.17
52 Week Low
$29.16
$10.70
52 Week High
$57.65
$32.06

Technical Indicators

Market Signals
Indicator
SUPN
NVCR
Relative Strength Index (RSI) 69.13 59.06
Support Level $47.98 $12.30
Resistance Level $52.11 $13.97
Average True Range (ATR) 1.53 0.56
MACD 0.72 0.09
Stochastic Oscillator 93.20 76.23

Price Performance

Historical Comparison
SUPN
NVCR

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Share on Social Networks: